Navigation Links
MannKind Corporation Response to Recent Market Events
Date:3/10/2008

f meal-time insulin observed in healthy individuals, but which is absent from patients with diabetes. MannKind believes that by mimicking the normal physiologic release of meal-time insulin, Technosphere(R) Insulin will be positioned as the only insulin therapy that effectively addresses post-prandial glucose excursions.

MannKind is only beginning to explore the opportunities associated with the ability to deliver a peptide hormone in ways that mimic normal hormone physiology. The data from MannKind's pivotal Phase 3 trials of Technosphere(R) Insulin will start to become available in the third quarter of 2008. In the meantime, in a Phase 1 trial of MKC253, another Technosphere(R)-based product, blood levels of GLP-1 were observed to peak within three minutes of administration, which may mimic the natural short pulse of GLP-1 that is produced in a healthy individual in response to glucose ingestion. Following administration of MKC253, study subjects experienced a dose-dependent increase in insulin levels and a decrease in glucose levels. Even at the highest doses of MKC253, subjects did not report any sweating, nausea or vomiting whereas those side effects are associated with the use of injectable GLP-1 products that do not mimic the natural, pulsatile feature of this hormone. These data will be presented in detail at the upcoming meeting of the American Diabetes Association.

MannKind believes that a significant need exists for products that offer efficacy and safety advantages in the delivery of peptide hormones. MannKind is committed to continuing the clinical development of Technosphere(R) Insulin and MKC253. A third peptide hormone for the treatment of obesity is in preclinical development. Currently, MannKind has sufficient financial resources to fund these programs and others through the end of 2009. It is MannKind's intention to bring these treatments to patients in collaboration with a leading pharmaceutical partner who shares a commitment to im
'/>"/>

SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. MannKind to Present at the UBS Global Life Sciences Conference
2. MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock
3. MannKind Announces Positive Results from a Phase 1a Study of a GLP-1 Formulation
4. MannKind to Present at the Piper Jaffray Healthcare Conference
5. MannKind to Present at the Wachovia 2008 Healthcare Conference
6. MannKind to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
7. MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on March 4, 2008
8. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
9. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
10. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... have developed a unique nanoscale device that for ... The discovery could have major implications for creating ... and communication. , The research paper by University ... Mo Li and his graduate student Huan Li ... the October issue of Nature Nanotechnology . ...
(Date:9/22/2014)... Rhinebeck, NY (PRWEB) September 22, 2014 ... commitment helping those in pain end their suffering, restoring ... sustainable healthcare model. This is only possible because of ... relief and healing cream technology a reality. , ... in Rhinebeck, NY, by Lou Paradise (president, chief of ...
(Date:9/22/2014)... WORCESTER, Mass. and TORONTO ... Biotechnology Corporation ( www.generex.com ) (OTCBB:GNBT) today announced ... University Health Network (UHN) pursuant to which UHN,s ... spearhead the Company,s buccal insulin refinement project.  The ... insulin bioavailability of Generex Oral-lyn™, the Company,s proprietary ...
(Date:9/22/2014)... September 22, 2014 METTLER TOLEDO ... and pallet measuring device CNS110 ScanTape™ . ... data entry, offering greater ease and accuracy for ... result can significantly enhance productivity—an important benefit for ... processing volume equals profits. , Usable at ...
Breaking Biology Technology:Engineers show light can play seesaw at the nanoscale 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 3Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 4Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 5Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 6Generex Collaborates with University Health Network for Buccal Insulin Project 2Generex Collaborates with University Health Network for Buccal Insulin Project 3Generex Collaborates with University Health Network for Buccal Insulin Project 4ScanTape™ Handheld Dimensioner Increases Processing Volume 2
... - Immunocytokine Combining Peregrine,s Anti-PS Antibodies and IL-2,Protected 80% of Animals From a Lethal Challenge ... ... at International Conference on Vascular Targeted, Therapies in Oncology Further Supports a Second ... ...
... Oct. 5 VioQuest,Pharmaceuticals (OTC Bulletin Board: VQPH), ... and,commercializing targeted cancer therapeutics, announced today that it ... 11, 2007 at 2:00 p.m.,Pacific Time at the ... San Francisco.,Daniel Greenleaf, VioQuest,s president and CEO, is ...
... Corporation,(Nasdaq: IOMI ) today announced that Stanley C. ... at the Natixis,Bleichroeder Hidden Gems Conference in New York ... at 2:45 p.m. Eastern Time in the in,Union Square ... live audio webcast or the subsequent archived recording,log on ...
Cached Biology Technology:New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrine's Anti-PS Technology Platform 2New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrine's Anti-PS Technology Platform 3New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrine's Anti-PS Technology Platform 4VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco 2VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco 3
(Date:9/21/2014)... CAMBRIDGE, MA -- In recent years, new strains of ... antibiotics. Each year, these superbugs, including drug-resistant forms of ... nationwide, and kill at least 23,000. Despite the urgent ... new classes of antibiotics in the past decade. , ... on these superbugs. Using a gene-editing system that can ...
(Date:9/19/2014)... dinosaurs a newly discovered hadrosaur with a ... Rhinorex condrupus by paleontologists from North ... in what is now Utah approximately 75 million ... Rhinorex, which translates roughly into "King Nose," was ... Cretaceous hadrosaurs like Parasaurolophus and Edmontosaurus. Hadrosaurs are ...
(Date:9/19/2014)... sense of fairness did not evolve for the sake ... the benefits of continued cooperation, so say Frans de ... review article about inequity aversion (IA), which is defined ... is published in Science . , Their ... IA-related studies to address their hypothesis that it is ...
Breaking Biology News(10 mins):Battling superbugs 2Battling superbugs 3Battling superbugs 4New hadrosaur noses into spotlight 2Evolution of responses to (un)fairness 2Evolution of responses to (un)fairness 3
... breath may indicate how susceptible they are to weight gain, ... Endocrine Society,s Journal of Clinical Endocrinology & Metabolism ... hydrogen and methane gases are more likely to have a ... to the findings. The combination of the two gases signals ...
... the early 1940s, California fishermen hauled in a historic bounty of ... "Cannery Row" novel. But by the end of the decade the ... all go? According to a new study led by scientists at ... the sardine mystery are a dynamic and interconnected moving target. ...
... March 25, 2013 Until now most experimental vaccines ... effectiveness. But a new vaccine has proven highly effective against ... is also effective against the H9 subtype of avian influenza. ... Journal of Virology . The strength of ...
Cached Biology News:Microorganisms detected via breath test linked to body mass, fat accumulation 2Predictions of climate impacts on fisheries can be a mirage 2Cleverly designed vaccine blocks H5 avian influenza in models 2
...
... SpliceArray service, ExonHit can design custom microarrays ... your gene list. Proprietary algorithms are ... microarray probes from high quality, spliced cDNAs ... event contained in a custom SpliceArray is ...
... binding specificity and signaling of the members ... be modified by alternative splicing--which has important ... you can perform a classical expression profiling ... different alternatively spliced forms of the gene ...
Mouse monoclonal antibody raised against a partial recombinant ST3GAL2. NCBI Entrez Gene ID = ST3GAL2...
Biology Products: